Multifocal squamous cell carcinomas in an HIV-infected patient with a long-term voriconazole therapy

AIDS

Volumn 22, Issue 7, 2008, Pages 905-906

  Brunel, Anne Sophie ^a   Fraisse, Thibaut ^a   Lechiche, Catherine ^a   Pinzani, Véronique ^b   Mauboussin, Jean Marc ^a   Sotto, Albert ^a  

^a NÎMES UNIVERSITY HOSPITAL   (France)

^b LAPEYRONIE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; DIDANOSINE; DOXORUBICIN; ENFUVIRTIDE; FLUCONAZOLE; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; POSACONAZOLE; SAQUINAVIR; TENOFOVIR; VORICONAZOLE; ZIDOVUDINE;

ANAMNESIS; ANGIONEUROTIC EDEMA; ASPERGILLOSIS; CHEILITIS; CYTOMEGALOVIRUS INFECTION; DISCOID LUPUS ERYTHEMATOSUS; DISEASE ASSOCIATION; DISEASE COURSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ERYTHEMA; EXFOLIATIVE DERMATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPOSI SARCOMA; LABORATORY TEST; LETTER; LONG TERM CARE; LUPUS VULGARIS; MULTIPLE CANCER; MYCOSIS; OROPHARYNX CANDIDIASIS; PHOTOAGING; PHOTOTOXICITY; PRIORITY JOURNAL; PSEUDOPORPHYRIA; RASH; SIDE EFFECT; SQUAMOUS CELL CARCINOMA; STEVENS JOHNSON SYNDROME; SUN EXPOSURE; TOXIC EPIDERMAL NECROLYSIS; TREATMENT FAILURE; VISUAL DISORDER;

ANTIFUNGAL AGENTS; CARCINOMA, SQUAMOUS CELL; HIV; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PYRIMIDINES; SKIN NEOPLASMS; TRIAZOLES;

EID: 42449150341     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3282f706a9     Document Type: Letter

References (15)

1. Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis 2003; 36:630-637.
2. Jeu L, Piacenti FJ, Lyakhovetskiy AG, Fung HB. Voriconazole. Clin Ther 2003; 25:1321-1381.
3. Eiden C, Peyrière H, Cociglio M, Djezzar S, Hansel S, Blayac JP, et al. Adverse effects of voriconazole: analysis of the French Pharmacovigilance database. Ann Pharmacother 2007; 41:755-763.
4. Denning DW, Ribaud P, Milpied M, Caillot D, Herbrecht R, Thiel E, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002; 34:563-571.
5. McCarthy KL, Playford EG, Looke DF, Whitby M. Severe photosensitivity causing multifocal squamous cell carcinomas secondary to prolonged voriconazole therapy. Clin Infect Dis 2007; 44:e55-e56.
6. Racette AJ, Roenigk HH, Hansen R, Mendelson D, Park A. Photoaging and phototoxicity from long-term voriconazole treatment in a fifteen-year-old girl. J Am Acad Dermatol 2005; 52 (Suppl 1):S81-S85.
7. Auffret N, Janssen F, Chevalier P, Guillemain R, Amrein C, Le Beller C. Voriconazole photosensitivity: 7 cases. Ann Dermatol Venereol 2006; 133:330-332.
8. Denning DW, Griffiths CEM. Muco-cutaneous retinoid effects and facial erythema related to the novel triazole antifungal agent voriconazole. Clin Exp Dermatol 2001; 26:648-653.
9. Sharp MT, Horn TD. Pseudoporphyria induced by voriconazole. J Am Acad Dermatol 2005; 53 (Suppl 2):341-345.
10. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30:239-245.
11. Maurer TA, Christian KV, Kerschmann RL, Berzin B, Palefsky JM, Payne D, et al. Cutaneous squamous cell carcinoma in human immunodeficiency virus-infected patients. A study of epidemiologic risk factors, human papillomavirus, and p53 expression. Arch Dermatol 1997; 133:577-583.
12. Wilkins K, Turner R, Dolev JC, LeBoit PE, Berger TG, Maurer TA. Cutaneous malignancy and human immunodeficiency virus disease. J Am Acad Dermatol 2006; 54:189-206.
13. Goedert JJ, Cote TR, Virgo P, Scoppa SM, Kingma DW, Gail MH, et al. Spectrum of AIDS-associated malignant disorders. Lancet 1998; 351:1833-1839.
14. Lobo DV, Chu P, Grekin RC, Berger TG. Nonmelanoma skin cancers and infection with the human immunodeficiency virus. Arch Dermatol 1992; 128:623-627.
15. Nguyen P, Vin-Christian K, Ming ME, Berger T. Aggressive squamous cell carcinomas in persons infected with the human immunodeficiency virus. Arch Dermatol 2002; 138:758-763.